


04-08-04



**PATENT**

Attorney Docket No. 225730

Client Reference No.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Travis, Craig R.

Group Art Unit: 1724

Application No. 10/738,457

Examiner: Unassigned

Filed: December 16, 2003

For: METHODS AND COMPOUNDS FOR  
INHIBITING EICOSANOID  
METABOLISM AND PLATELET  
AGGREGATION

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

- ☒ **within** any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under

37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

- ☐ **after** (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:

☐ the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).

*or*

☐ the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).

- ☐ **after** the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).

- ☐ **after** the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and **within** thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).

NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.

### Copies of the References

- ☒ Copies of all of the references listed on the enclosed Form 1449 are enclosed herewith.
- ☒ This patent application was filed after June 30, 2003. Accordingly, copies of U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith (see Official Gazette Notice of August 5, 2003). Copies of other references identified on the accompanying Form 1449 are enclosed herewith.
- ☒ Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
- ☐ A copy of the foreign search report is enclosed herewith.

- ☐ The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLICATIONS		Status ( <i>check one</i> )		
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1.				
2.				
3.				

**Statement under 37 CFR 1.97(e)**

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

**Statement under 37 CFR 1.704(d)**

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

**Fees**

- ☒ No fee is owed by the applicant(s).
- ☐ The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith.

In re Appln. of Travis, Craig R.  
Application No. 10/738,457

**Method of Payment of Fees**


- ☐ Attached is a check in the amount of \$ .  
☐ Charge Deposit Account No. 12-1216 in the amount of \$ . (A duplicate copy of this communication is enclosed for that purpose.)

**Authorization to Charge Additional Fees**

- ☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

**Instructions as to Overpayment**

- ☒ Credit Account No. 12-1216.  
☐ Refund



M. Daniel Hefner, Reg. No. 41,826  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: April 7, 2004

**CERTIFICATION OF EXPRESS MAIL**

"Express Mail" Label Number: EV 335719878 US

Date of Deposit: April 7, 2004

I hereby certify that this "INFORMATION DISCLOSURE STATEMENT" and all accompanying documents are being deposited with the United States Postal Service "Express Mail Post Office To Addressee" Service under 37 CFR 1.10 on the date indicated below and is addressed to: Mail Stop: , Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Christina Masters		April 7, 2004
Name of Person Signing	Signature	Date

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

8

**Complete if Known**

Application Number	10/738,457
Filing Date	December 16, 2003
First Named Inventor	Travis, Craig R.
Group Art Unit	1724
Examiner Name	Unassigned
Attorney Docket Number	225730

**U.S. PATENT DOCUMENTS**

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	AA	2,304,669	A	Adams	Dec. 8, 1942	
	AB	US 564,827	A	Adams	Oct. 16, 1944	
	AC	2,509,386	A	Adams	May 30, 1950	
	AD	3,388,136	A	Taylor	June 11, 1968	
	AE	3,507,885	A	Fahrenholtz	April 21, 1970	
	AF	3,649,650	A	Razdan et al.	Mar. 14, 1972	
	AG	3,668,224	A	Petrizilka	June 6, 1972	
	AH	3,799,946	A	Loev	Mar. 26, 1974	
	AI	3,856,820	A	Love	Dec. 24, 1974	
	AJ	3,856,821	A	Loev	Dec. 24, 1974	
	AK	3,856,822	A	Bender et al.	Dec. 24, 1974	
	AL	3,864,492	A	Fager et al.	Feb. 4, 1975	
	AM	3,873,576	A	Petzilka	Mar. 25, 1975	
	AN	3,897,306	A	Vidic et al.	July 29, 1975	
	AO	3,919,322	A	Brossi et al.	Nov. 11, 1975	
	AP	3,928,598	A	Archer	Dec. 23, 1975	
	AQ	4,018,766	A	Brown et al.	April 19, 1977	
	AR	4,018,777	A	Zaugg et al.	April 19, 1977	
	AS	4,020,098	A	Gosteli	April 26, 1977	
	AT	4,054,583	A	Blanchard et al.	Oct. 18, 1977	
	AU	4,064,009	A	Fukuda et al.	Dec. 20, 1977	
	AV	4,087,545	A	Archer et al.	May 2, 1978	
	AW	4,104,282	A	Fukuda et al.	Aug. 1, 1978	
	AX	4,116,979	A	Razdan et al.	Sept. 26, 1978	
	AY	4,140,701	A	Ryan	Feb. 20, 1979	
	AZ	4,143,139	A	Bindra	Mar. 6, 1979	
	BA	4,180,669	A	Winn	Dec. 25, 1979	
	BB	4,195,078	A	Conine	Mar. 25, 1980	
	BC	4,249,027	A	Gosteli	Feb. 3, 1981	
	BD	4,309,545	A	Johnson	Jan. 5, 1982	
	BE	4,315,862	A	Elsohly et al.	Feb. 16, 1982	
	BF	4,351,840	A	Pirie	Sept. 28, 1982	
	BG	4,405,626	A	Johnson	Sept. 20, 1983	
	BH	4,464,378	A	Hussain	Aug. 7, 1984	
	BI	4,599,327	A	Nogradi et al.	July 8, 1986	
	BJ	4,661,505	A	Marshall et al.	April 28, 1987	
	BK	4,758,597	A	Martin et al.	July 19, 1988	
	BL	4,777,298	A	Marshall et al.	Oct. 11, 1988	
	BM	4,833,073	A	McNally et al.	May 23, 1989	
	BN	4,837,228	A	Elsohly et al.	June 6, 1989	
	BO	4,841,078	A	Eggler et al.	June 20, 1989	
	BP	4,847,290	A	Burstein	July 11, 1989	
	BQ	4,876,276	A	Mechoulam et al.	Oct. 24, 1989	
	BR	4,933,368	A	Satzinger et al.	June 12, 1990	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	2	of	8
-------	---	----	---

Application Number	10/738,457
Filing Date	December 16, 2003
First Named Inventor	Travis, Craig R.
Group Art Unit	1724
Examiner Name	Unassigned
Attorney Docket Number	225730

[illegible]

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/738,457
				Filing Date	December 16, 2003
				First Named Inventor	Travis, Craig R.
				Group Art Unit	1724
				Examiner Name	Unassigned
Sheet	3	of	8	Attorney Docket Number	225730

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	DC	EP	0 494 665	B1	Stoss et al.	Jan. 9, 1992		
	DD	HU	188299	B	Szerves Vegyipari Fejlesztő Kozos Vallalat	Mar. 28, 1986		X <sup>+</sup>
	DE	JP	02-101036	H	Yamanouchi Seiyaky KK	April 12, 1990	X	
	DF	JP	4-208280	A	Matsushita Electric Ind. Co. Ltd.	Nov. 30, 1990		X <sup>+</sup>
	DG	JP	JP2000191520	A	Sakuma Kazuo	July 11, 2000		X <sup>+</sup>
	DH	WO	97/11668	A2	Yissum Research Development Co. of the Hebrew University	April 3, 1997		
	DI	WO	97/40006	A2	Cancer Research Campaign Tech. Ltd.	Oct. 30, 1997		
	DJ	WO	99/20268	A1	Atlantic Pharm., Inc.	April 29, 1999		
	DK	WO	99/32107	A1	Danbiosyst UK Ltd.	July 1, 1999		
	DL	WO	99/51560	A1	Yissum Research Development Co. of the Hebrew University	Oct. 14, 1999		
	DM	WO	99/52524	A1	The Mathilda & Terence Kennedy Insitute of Rheumatology	Oct. 21, 1999		
	DN	WO	99/53917	A1	The Government of the United States of America	Oct. 28, 1999		

OTHER - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.					Translation	
							Yes	No**
	DO	Abrams, J. of Acq. Immun. Def. Syn., 25, 74-80 (2000)						
	DP	Adams et al., J. Med. Chem., 70, 662-68 (1947)						
	DQ	Adams et al., "New Analogs of Tetrahydrocannabinol," 71, 1624-28 (1949)						
	DR	Akamanchi et al., Pharm. Pharmacol. Commun., 5, 323-329 (1999)						
	DS	Arisawa et al., Chem. Pharm. Bull., 37, 9, 2431-2434 (1989)						
	DT	Baek et al., Arch. Pharm. Res. 21, 3, 353-356 (1998)						
	DU	Baek et al., Arch. Pharmacol Res., 19, 3, 228-230 (1996)						
	DV	Baeuerle et al., Ann. Rev. Immunol., 12, 141-79 (1994)						
	DW	Barth, Exp. Opin. Ther. Patents, 8, 3, 301-313, (1998)						
	DX	Bennett et al., Marijuana and Medicine, 717-721 (Humana Press 1999)						
	DY	Beutler, J. Nat. Prod., 61, 1509-1512 (1998)						
	DZ	Bhargava, General Pharmacology, 9, 195-213 (1978)						
	EA	Biswas et al., J. of Acq. Immun. Def. Syn. and Hum. Retrovirol., 18, 426-34 (1998)						
	EB	Bornheim, Biochem. Pharm., 36, 955-961 (2000)						
	EC	Bornheim, "Cannabidiol-Effect on Cytochro P450 Isozymes," Abstract, NIH Grant No. 5R01DA04265-13						
	ED	Bornheim, Chem. Res. Toxicol., 11, 1209-16 (1998)						
	EE	Braitstein et al., AIDS 2001, 15, 4, 532-533 (2000)						
	EF	Brenneisen et al. Int. J. of Clin. Pharmacol. Ther., 34, 446-52 (1996)						
	EG	Buchwald et al., Pharamazie, 55, 196-201 (2000)						

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/738,457
				Filing Date	December 16, 2003
				First Named Inventor	Travis, Craig R.
				Group Art Unit	1724
				Examiner Name	Unassigned
Sheet	4	of	8	Attorney Docket Number	225730

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
	EH	Burstein et al., <u>J. Pharmacol. and Experimental Therapeutics</u> , <b>251</b> , 2, 531-535 (1989)			
	EI	Burstein et al., <u>Biochemical Pharm.</u> , <b>29</b> , 2153-2154 (1980)			
	EJ	Burstein et al., <u>Pharmacol. Ther.</u> , <b>82</b> , 87-96 (1999)			
	EK	Busch-Petersen et al., <u>J. Med. Chem.</u> , <b>39</b> , 3790-96 (1996)			
	EL	Bustos et al., <u>J. Clin. Invest.</u> , <b>100</b> , 5, 1150-1158 (1997)			
	EM	Butera et al., <u>Aids Res. Hum. Retrovir.</u> , <b>8</b> , 991-95 (1992)			
	EN	Cabral et al., <u>Adv. Biosci.</u> , <b>80</b> , 93-105 (1991)			
	EO	Carchman et al., <u>Marihuana: Chem., Biochem.</u> , <b>28</b> , 329-345 (1975)			
	EP	Charalambous et al., <u>Pharm Biochem. Behav.</u> , <b>40</b> , 509-12 (1991)			
	EQ	Chen et al., <u>Chem. Commun.</u> , 2769-2770 (1998)			
	ER	Colasanti et al., <u>Exp. Eye Res.</u> , <b>38</b> , 63-71(1984)			
	ES	Colasanti et al., <u>Exp. Eye Res.</u> , <b>39</b> , 251-259 (1984)			
	ET	Corr et al., "Selected metabolic alterations in the ischemic heart and their contributions to arrhythmogenesis," Abstract, NIH Grant No. 7543431UI95362134			
	EU	Daaka et al., <u>DNA Cell Biol.</u> , <b>16</b> , 301-09 (1997)			
	EV	Del Real et al., <u>AIDS</u> , <b>12</b> , 865-72 (1998)			
	EW	Desoize, <u>Anticancer Res.</u> , <b>14</b> , 2291-94 (1994)			
	EX	Dewhirst, <u>Prostaglandins</u> , <b>20</b> , 209-22 (1980)			
	EY	Di Franco, <u>AEP</u> , <b>6</b> , 283-89 (1996)			
	EZ	Dol et al., <u>Eur. J. Org. Chem.</u> , 359-64 (1998)			
	FA	Dominianni et al., <u>J. Org. Chem.</u> , <b>42</b> , 344-46 (1977)			
	FB	Dumais et al., <u>J Biol Chem.</u> , <b>42</b> , 27306-14 (1998)			
	FC	Eisohly et al., <u>J. of Pharm. Sciences</u> , <b>71</b> , 12, 1319-1323 (1982)			
	FD	Elkin et al., Abstract, Delta-9 Tetrahydrocannabinol a novel treatment for inflammatory demyelination, <u>Experimental Biology</u> , Annual meeting, Abstract, Apr. 29 (1987)			
	FE	Evans et al., <u>Biochem. Pharm.</u> , <b>36</b> , 2035-37 (1987)			
	FF	Evans, <u>Planta Med.</u> , <b>57</b> , S60-S67 (1991)			
	FG	Felder et al., <u>Mol. Pharmacol.</u> , <b>42</b> , 838-45 (1992)			
	FH	Fiddler et al., <u>Supp. I Circulation</u> , <b>81</b> , 1, I-69-I-78 (1990)			
	FI	Formukong et al., <u>Dept. of Pharm., School of Pharm., University of London</u> , 79P Abstract.			
	FJ	Formukong et al., <u>J. Pharm. Pharmacol</u> , <b>41</b> , 705-709 (1989)			
	FK	Foye et al., <u>Princ. Med. Chemistry</u> , Forth Edition, 246-98 (Williams & Wilkins 1995)			
	FL	Fürstner et al., <u>J. Org. Chem.</u> , <b>62</b> , 2332-36 (1997)			
	FM	Gallily et al., <u>J. Pharmacol. Exp. Ther.</u> , <b>283</b> , 918-924 (1997)			
	FN	Galve-Roperh et al., <u>Nat. Med.</u> , <b>6</b> , 313-19 (2000)			
	FO	Gareau et al., <u>Bioorg. Med. Chem. Let.</u> , <b>6</b> , 189-94 (1996)			
	FP	Gervaix et al., <u>Proc. Natl. Acad. Sci. (U.S.A.)</u> , <b>94</b> , 4653-58 (1997)			
	FQ	Gollapudi et al., <u>Aids Res. Hum. Retrovir.</u> , <b>14</b> , 499-504 (1998)			
	FR	Gorter et al., <u>Cannabis in der Behandlung krebskranker und HIV-positiver Patienten Die erste klinische Cannabis-Studie in Deutschland</u> , Brohanf Symposium, 691-92 (1997) (with translation)			
	FS	Granelli-Piperno et al., <u>Proc. Natl. Acad. Sci. (U.S.A.)</u> , <b>92</b> , 10944-48 (1995)			
	FT	Griffin et al., <u>Br. J. Pharmacol.</u> , <b>126</b> , 1575-84, (1999)			



Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/738,457	
			Filing Date	December 16, 2003	
			First Named Inventor	Travis, Craig R.	
			Group Art Unit	1724	
			Examiner Name	Unassigned	
Sheet	5	of	8	Attorney Docket Number	225730

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	FU	Gruol, "Drug Effects on Neuronal Development in Pediatric Aids," Abstract, NIH Grant No. 1R01DA10187-01A2		
	FV	Gurwitz et al., <u>Molecular Medicine Today</u> , May, 196-200 (1998)		
	FW	Hammer et al., <u>The Scientist</u> , 13, Feb. 15 (1999)		
	FX	Harris et al., <u>Pharm. Of Marihuana</u> , 749-762 (1976)		
	FY	Harris et al., <u>The Pharmacologist</u> , 17, 2, Abstract 492 (1975)		
	FZ	Hartmann et al., <u>J. Med. Chem.</u> , 23, 841-848 (1980)		
	GA	Harvey et al., <u>Biomed. Mass Spect.</u> , 4, 364-70 (1977)		
	GB	Hembree III et al., <u>Marihuana and Medicine</u> , (1999)		
	GC	Herring et al., <u>Biochem. Pharmacol.</u> , 55, 1013-23 (1998)		
	GD	Hladyszowski et al., <u>Free Rad. Res.</u> , 28, 359-68 (1997)		
	GE	Huang et al., <u>Marihuana and Medicine</u> , (1999)		
	GF	Huffman, "Synthesis of Cannabinoids Analogues and Metabolites," Abstract, NIH Grant No. 5R01DA03590-11		
	GG	Huffman et al., <u>Bioor. Med. Chem.</u> , 6, 2383-96 (1998)		
	GH	Huffman et al., <u>Bioorg Med. Chem.</u> , 6, 2281-88 (1998)		
	GI	Huffman et al., <u>J. Med Chem.</u> , 39, 3875-77 (1996)		
	GJ	Huffman et al., <u>Life Sci.</u> , 56, 2021-24 (1995)		
	GK	Itokawa et al., <u>Chem. Pharm. Bull.</u> , 35, 7, 3016-3020 (1987)		
	GL	Jobin et al., <u>Thromb. Diath. Haemorrh.</u> , 22, 3, 466-481 (1969)		
	GM	Joy et al., "Consequences of Marijuana Use and Abuse," in <u>Marijuana and Medicine</u> , 115-21, (National Academy Press, 1999)		
	GN	Kalofoutis et al., <u>Pharm. Biochem. &amp; Behavior</u> , 12, 697-699 (1979)		
	GO	Kaminski, <u>J. Neuroimmunol.</u> , 83, 124-32 (1998)		
	GP	Kaminski, <u>Toxicol. Let.</u> , 102-103, 59-63 (1998)		
	GQ	Kapeghian et al., <u>Gen. Pharmacol.</u> , 14, 3, 361-363 (1983)		
	GR	Kawakami et al., <u>Int. J. Immunopharmacol.</u> , 10, 485-488 (1988)		
	GS	Khanolkar et al., <u>Chem. and Physics of Lipids</u> , 108, 37-52 (2000)		
	GT	Kitagawa et al., <u>Chem. Pharm. Bull.</u> , 39, 4, 1062-1064 (1991)		
	GU	Klein et al., <u>J. Neuroimmunol.</u> , 83, 102-15 (1998)		
	GV	Koch et al. <u>Synthesis of 5-Alkylresorcinols</u> , (Unclassified Report) (1962)		
	GW	Kozubek et al., <u>Chem. Rev.</u> , 99, 1-25 (1999)		
	GX	Lancz et al., <u>Proc. Soc. Exp. Biol. Med.</u> , 4, 401-04 (1991)		
	GY	Lemberger et al., <u>Clin. Pharmacol. Ther.</u> , 18, 720-26 (1975)		
	GZ	Liddle et al., <u>Bioorg Med. Chem. Let.</u> , 8, 2223-26 (1998)		
	HA	Loev et al., <u>J. Med. Chem.</u> , 11, 1234-35 (1974)		
	HB	Loev et al., <u>J. Med. Chem.</u> , 16, 1200-06 (1973)		
	HC	Lyman et al., <u>J. Neuroimmunol.</u> , 23, 73-81 (1989)		
	HD	Lytollis et al., <u>J. Am. Chem. Soc.</u> , 117, 12683-90 (1995)		
	HE	Madani et al., <u>Proc. Natl. Acad. Sci. (U.S.A.)</u> , 95, 8005-10 (1998)		
	HF	Mahadevan et al., <u>J. Med. Chem.</u> , 43, 3778-3785 (2000)		
	HG	Makriyannis et al., <u>Life Sci.</u> , 47, 2173-84 (1990)		
	HH	Martin et al., <u>Pharm. Biochem. Behav.</u> , 46, 295-301 (1993)		
	HI	Matsuyama et al., <u>AIDS</u> , 5, 1405-17 (1991)		
	HJ	McFerling, <u>Chicago Tribune</u> , Dec. 18 (1998)		

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/738,457
				Filing Date	December 16, 2003
				First Named Inventor	Travis, Craig R.
				Group Art Unit	1724
				Examiner Name	Unassigned
Sheet	6	of	8	Attorney Docket Number	225730

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
	HK	McPartland et al., <u>Alt. Ther.</u> , <b>5</b> , 57-62 (1999)			
	HL	Mishkin et al., <u>Proc. Soc. Exp. Biol. Med.</u> , <b>185</b> , 41-48 (1987)			
	HM	Mon et al., <u>Biochem. Pharmacol.</u> , <b>30</b> , 31-43 (1981)			
	HN	Mon et al., <u>Biochem. Pharmacol.</u> , <b>30</b> , 45-58 (1981)			
	HO	Morse et al., <u>Life Sci.</u> , <b>56</b> , 1957-62 (1995)			
	HP	Nahas et al., "Inhibitor effect of 5-amyresorcinol on lymphoblastic tranformation, C.R." <u>Hebd. Seances Acad. Sci., Ser. D</u> (1974) (and English translation)	X		
	HQ	Nahas et al., <u>Fed. Pro.</u> , <b>36</b> , 1748-52 (1977)			
	HR	Nahas et al., <u>Pharmacology</u> , poster session 1848.			
	HS	Nathan et al., <u>Can. J. Physiol. Pharmacol.</u> , <b>70</b> , 1305-1308 (1992)			
	HT	Nichols et al., <u>Life Sci.</u> , <b>21</b> , 9, 1245-1248 (1977)			
	HU	Noe et al., <u>Drugs of Abuse, Immunomodulation and AIDS</u> , <b>25</b> , 223-24 (Plenum Press, 1998)			
	HV	Noe et al., <u>Advances in Experimental Medicine and Biology</u> , <b>437</b> , 223-29 (1998)			
	HW	Novak et al., <u>Tetrahedron Let.</u> , 253-54 (1982)			
	HX	Ongradi et al., <u>Pathol Oncol Res.</u> , <b>4</b> , 191-199 (1998)			
	HY	Papahatjis et al., <u>J. Med. Chem.</u> , <b>41</b> , 1195-200 (1998)			
	HZ	Pars et al., <u>J. Med. Chem</u> , <b>19</b> , 455-53 (1976)			
	IA	Pate, <u>J. Int. Hemp. Assoc.</u> , <b>2</b> , 74-76 (1995)			
	IB	Pearce et al., <u>J. of Med. Chem.</u> , <b>37</b> , 526-541 (1994)			
	IC	Penglis et al., <u>J. Immunol.</u> , <b>165</b> , 3, 1605-1611 (2000)			
	ID	Pertwee, <u>Pharmacol. Ther.</u> , <b>74</b> , 129-80 (1997)			
	IE	Petit et al., <u>Life Sci.</u> , <b>63</b> , PL 1-6 (1998)			
	IF	Pillai et al. <u>Arch Toxicol</u> , <b>65</b> , 609-617 (1991)			
	IG	Piomelli, <u>Nat. Med.</u> , <b>6</b> , 255-56 (2000)			
	IH	Pitt et al., <u>J. Org. Chem.</u> , <b>44</b> , 5, 677-683 (1979)			
	II	Polansky et al., "Eicosanoid production and glucocorticoid regulatory mechanisms in cultured human trabecular meshwork cells," Abstract, NIH Grant No. 2508121UI90017695			
	IJ	Pop, <u>Cur. Op. Chem. Biol.</u> , <b>3</b> , 418-425 (1999)			
	IK	Promes et al., <u>Emergency Medicine Report</u> , <b>19</b> , 24, 258-268 (1998)			
	IL	Razdan et al., <u>J. Med. Chem.</u> , <b>19</b> , 454-60 (1976)			
	IM	Razdan, <u>Pharmacolog Rev.</u> <b>38</b> , 75-148 (1986)			
	IN	Razdan, "Synthesis of Tetrahydrocannabino/related compounds," Abstract, NIH Grant 5R01DA05488-12			
	IO	Reggio et al., <u>J. Med. Chem.</u> , <b>40</b> , 3312-18 (1997)			
	IP	Reggio et al., <u>Life Sci.</u> , <b>56</b> , 2025-32 (1995)			
	IQ	Rhee et al., <u>J. Med. Chem.</u> , <b>40</b> , 3228-33 (1997)			
	IR	Rhee et al., <u>J. Neurochem.</u> <b>71</b> , 1525-34 (1998)			
	IS	Ritch, <u>Current Opinion in Ophthalmology</u> , <b>11</b> , 78-84 (2000)			
	IT	Rome et al., <u>Proc. Nat. Acad. Sci.</u> , <b>72</b> , 4863-4865 (1975)			
	IU	Ross et al., <u>Br. J. Pharmacol.</u> , <b>126</b> , 665-72 (1999)			
	IV	Scannell et al., <u>J. Am. Chem. Soc.</u> , <b>110</b> , 3651-53 (1988)			
	IW	Schuel et al., <u>Marihuana and Medicine</u> , (1999)			
	IX	Seltzman, <u>Cur. Med. Chem.</u> , <b>6</b> , 685-704 (1999)			

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/738,457
				Filing Date	December 16, 2003
				First Named Inventor	Travis, Craig R.
				Group Art Unit	1724
				Examiner Name	Unassigned
Sheet	7	of	8	Attorney Docket Number	225730

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
	IY	Shen et al., <u>Prostaglandin Synthetase Inhibitors</u> , 19-31 (1974)			
	IZ	Showalter et al., <u>J. Pharm. Exp. Ther.</u> , <b>278</b> , 989-99 (1996)			
	JA	Sidney et al., <u>Amer. Journal of Public Health</u> , <b>87</b> , 585-90 (1997)			
	JB	Singh et al., <u>J. Am. Chem. Soc.</u> , <b>117</b> , 12691-99 (1995)			
	JC	Singh et al., <u>J. Org. Chem.</u> , <b>61</b> , 7727-7727 (1996)			
	JD	Smith et al. <u>Marihuana and Medicine</u> , (1999)			
	JE	Specter, <u>Cannabinoids and Immunity to Viruses</u> , <b>18</b> , 131-34 (1996)			
	JF	Specter et al., <u>Drugs of Abuse and Immune Function</u> . <b>5</b> , 73-86 (1990)			
	JG	Specter et al., <u>FASEB</u> , <b>4</b> , A1021 Abstract (1990)			
	JH	Spira et al., <u>J. Exp. Med.</u> , <b>183</b> , 215-25 (1996)			
	JI	Sproncn et al, <u>Biochem. Pharm.</u> , <b>27</b> , 607-08 (1978)			
	JJ	Srivastava et al., <u>Immunopharmacology</u> , <b>40</b> , 179-85 (1998)			
	JK	Straus, <u>PNAS</u> , <b>97</b> , 17, 9363-9364 (2000)			
	JL	Sugaya et al., "New anti-inflammatory treatment strategy in Alzheimer's disease," Abstract, NIH Grant 10877525UI20334036			
	JM	Suter et al., <u>C.M. Suter and Arthur W. Weston</u> , <b>61</b> , 232-236 (1939)			
	JN	Tao et al., <u>Mol. Pharmacol.</u> , <b>55</b> , 605-13 (1999)			
	JO	The Herald, <u>HIV rebounds when pills cut back</u> , Oct 29, 12A (1998)			
	JP	Thomas et al., <u>J. Pharmacol. Exp. Ther.</u> , <b>255</b> , 624-30 (1990)			
	JQ	Thomas et al., <u>J. Pharmacol. Exp. Ther.</u> , <b>285</b> , 285-92 (1998)			
	JR	Thomas et al., <u>Mol. Pharmacol.</u> , <b>40</b> , 656-65 (1991)			
	JS	Timpone et al., <u>Aids Res. Hum. Retroviruses</u> , <b>13</b> , 305-315 (1997)			
	JT	Trinkl, press release of July 13, 2000 published on World Wide Web at <a href="http://www.ucsf.edu/pressrel/2000/07/071302.html">http://www.ucsf.edu/pressrel/2000/07/071302.html</a> and entitled "Marijuana does not appear to alter viral loads of HIV Patients taking Protease Inhibitors".			
	JU	Turner et al., <u>J. of Clinical Pharm.</u> , <b>21</b> , 283S-291S (1981)			
	JV	Usami et al., <u>Chem. Pharm. Bull.</u> , <b>46</b> , 9, 1462-1467 (1998)			
	JW	Voet et al., <u>Biochem.</u> , Chp. 23, (1995)			
	JX	Waksman, <u>J. of Autoimmunity</u> , suppl. 56 Abstract (1999)			
	JY	Warner et al., <u>Proc. Natl. Acad. Sci. USA, Pharmacology</u> , <b>96</b> , 7563-7568 (1999)			
	JZ	Watzl et al., <u>Drugs of Abuse, Immunity and Immunodeficiency</u> , 63-70 (Plenum Press 1991)			
	KA	Watzl et al., <u>Int. J. Immunopharmacol.</u> , <b>13</b> , 1091-1097 (1991)			
	KB	Weissman et al., <u>Nature</u> , <b>389</b> , 981-85 (1997)			
	KC	Weissman et al., <u>Pro. Natl. Acad. Sci. (U.S.A.)</u> , <b>90</b> , 2537-41 (1993)			
	KD	White et al., <u>Prostaglandins and Medicine</u> , <b>4</b> , 409-411 (1980)			
	KE	Whitfield et al., <u>Alcohol Clin. Exp. Res.</u> , <b>21</b> , 122-27 (1997)			
	KF	Wiley et al., <u>J. Pharmacol.</u> , <b>285</b> , 995-1004 (1998)			
	KG	Winn et al., <u>J. Med. Chem.</u> <b>19</b> , 461-71 (1976)			
	KH	Xie et al., <u>J. Med. Chem.</u> , <b>41</b> , 167-74 (1998)			
	KI	Yoshida et al., <u>Chem. Pharm. Bull.</u> , <b>43</b> , 2, 335-337 (1995)			
	KJ	Zheng et al., <u>Int. J. Immunopharmacol.</u> , <b>14</b> , 1445-1452 (1992)			
	KK	Zhu et al., <u>J. Exp. Ther.</u> , <b>286</b> , 2, 1103-09 (1998)			
	KL	Zimmerman et al., <u>Marihuana and Medicine</u> , (1999)			

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	8	of	8
-------	---	----	---

<b>Application Number</b>	10/738,457
<b>Filing Date</b>	December 16, 2003
<b>First Named Inventor</b>	Travis, Craig R.
<b>Group Art Unit</b>	1724
<b>Examiner Name</b>	Unassigned
<b>Attorney Docket Number</b>	225730

[illegible]

Date Considered

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).